Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Risankizumab-800CW imaging in IBD
NCT06606808Phase 2Recruiting
- Sponsor
- University Medical Center Groningen
- Start
- Nov 2024
- Primary completion
- Aug 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of risankizumab in Crohn's disease (CD), ulcerative colitis (UC), sponsored by University Medical Center Groningen. Started Nov 2024; status: recruiting.
02
Drugs
risankizumab
03
Conditions
Crohn's disease (CD)ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT06606808.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06606808.